## ISRG: Intuitive Surgical, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -2.3% below STRENGTH zone (3.0-6.0%); PEG 3.36 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($517.36)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. Intuitive Surgical (ISRG) stock: What to know before the U.S. market opens on Dec. 15, 2025**
- Source: ts2.tech | 20251214T221221 | Neutral | Relevance: 100%
- This article provides a comprehensive overview of key factors influencing Intuitive Surgical (ISRG) stock before the market opens on December 15, 2025. It highlights recent FDA clearances for its da Vinci SP system, increasing competition from Medtronic and Johnson & Johnson, Q3 2025 financial performance, ongoing product momentum, and analyst forecasts, all while considering the stock's premium valuation.

**2. Citi downgrades Intuitive Surgical (ISRG) to a Hold**
- Source: The Globe and Mail | 20251212T105412 | Somewhat-Bearish | Relevance: 100%
- Citi analyst Joanne Wuensch has downgraded Intuitive Surgical (ISRG) to a Hold rating and assigned a price target. Wuensch is a 4-star analyst with a 5.2% average return and a 58.59% success rate, focusing on the Healthcare sector. Intuitive Surgical reported a quarterly revenue of $2.51 billion and a net profit of $704.4 million for the quarter ending September 30.

**3. Intuitive wins 3 new indications for da Vinci SP system**
- Source: MedTech Dive | 20251211T171249 | Bullish | Relevance: 100%
- Intuitive Surgical's da Vinci SP surgical robot has received FDA clearance for three new indications: inguinal hernia repair, gallbladder removal, and appendectomy procedures. These new clearances aim to expand the adoption of the single-port platform, which allows surgeons to perform complex procedures through a single incision or natural orifice. The SP system, designed for narrow or deep spaces, is a growing part of Intuitive's business, with procedures performed using it rising by 91% in the third quarter.

**4. Intuitive Announces Expanded Indications for da Vinci SP**
- Source: GlobeNewswire | 20251210T210819 | Bullish | Relevance: 100%
- Intuitive (NASDAQ: ISRG) has announced that the U.S. FDA has cleared its da Vinci Single Port (SP) surgical system for expanded use in inguinal hernia repair, cholecystectomy, and appendectomy procedures. This expands on its existing clearances in urology, colorectal, thoracic, and transoral procedures. The da Vinci SP system allows surgeons to perform procedures through a single incision or natural orifice, offering enhanced visualization and precision, and is part of Intuitive's commitment to less invasive and profoundly better patient care.

**5. Intuitive Announces Expanded Indications for da Vinci SP**
- Source: GlobeNewswire | 20251210T161500 | Bullish | Relevance: 100%
- Intuitive (NASDAQ: ISRG) has announced that the U.S. FDA has cleared its da Vinci Single Port (SP) surgical system for expanded indications, including inguinal hernia repair, cholecystectomy, and appendectomy procedures. This clearance adds to the system's existing U.S. clearances in other surgical fields, allowing surgeons to perform procedures through a single incision with enhanced visualization and precision. The company emphasizes its commitment to less invasive care and improving patient outcomes through continuous innovation of its platforms.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-11 | Citigroup | $635 | $650 | -2% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-11 | Citigroup | down | Neutral |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($2.31M) |
| Sells | 14 ($32.28M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 35.6% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 4 |

**Top Holders:**
- Vanguard Group Inc: 9.4% (+0.8%)
- Blackrock Inc.: 8.8% (+0.1%)
- State Street Corpora: 4.3% (-0.1%)
- Price (T.Rowe) Assoc: 3.6% (-4.4%)
- Geode Capital Manage: 2.3% (+1.0%)

### Key Risks

1. Heavy insider selling: $32M sold (14 transactions in 90 days).
2. Valuation stretched: PEG 3.4x requires aggressive growth execution.
3. Market regime shift could impact high-beta names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 3.36 signals overvaluation risk, limited margin of safety. Forward P/E 55.8x stretched relative to 13% growth. Quality metrics strong (margin 29%). Balance sheet: strong liquidity (4.7x), low leverage (D/E 0.14). Analyst sentiment negative (1 target cuts vs 0 raises). Insider selling cluster ($32.3M in 90 days), potential headwind. Institutional flow bearish (4 selling vs 5 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $194.4B |
| Beta | 1.69 |
| 52W Range | $425.00 - $616.00 |
| Short Interest | 2.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.36 |
| Forward P/E | 55.8 |
| Current P/E | 62.8 |
| YoY Growth | 12.7% |
| EPS Direction | RISING |

### Technicals

MRS_10 weakening modestly (-0.6% over 5 days). Below STRENGTH zone by 5.3pp (needs >3.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.07x) but short-term weakness (below SMA20). MACD histogram bearish (-5.67), momentum weakening. RSI neutral at 44. OFD pattern: -SLN (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -2.31% (CS: 10) | Weak |
| RSI_14 | 43.8 | Neutral |
| MACD Histogram | -5.67 | Bearish |
| vs SMA20 | 0.965x | Below |
| vs SMA50 | 1.029x | Above |
| vs SMA200 | 1.067x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $542.32
- **Stop Loss:** $517.36 (4.6% risk)
- **Target:** $567.28 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 40
- **Position Value:** $21,692.80
- **Portfolio %:** 21.69%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX remains calm at 15.74 while breadth shows modest participation at 54%, suggesting selective positioning. FOMC meeting in 4 days creates near-term uncertainty but no systemic stress evident.*

### Earnings

**Next:** 2026-01-22 (Est: $2.24)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.99 | $2.40 | +20.7% |
| 2025Q2 | $1.92 | $2.19 | +14.1% |
| 2025Q1 | $1.73 | $1.81 | +4.4% |
| 2024Q4 | $1.79 | $2.21 | +23.7% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*